Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

DURHAM, NC — Projected lifetime treatment with the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) appears to be cost-effective vs warfarin for patients with atrial ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

A 2012 study using indirect comparisons indicated that apixaban had a lower risk of major hemorrhage compared with other DOACs. And a 2018 analysis based on claims data showed that apixaban carried ...

Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or warfarin. Image: Adobe Stock “The prescribing decisions for oral anticoagulants need to ...

In the PROACT Xa trial, which began enrollment in April 2020, patients with an On-X mechanical aortic valve were randomly allocated to receive anticoagulation with warfarin or apixaban.

ABSTRACT. Objectives: To investigate the journey to oral anticoagulant (OAC) access following formulary-related rejection of apixaban (Eliquis) and evaluate characteristics associated with failure ...

Apixaban Noninferior for VTE Recurrence, Superior for Bleeding. At 6 months, the incidence of recurrent symptomatic VTE or death related to VTE, the primary efficacy endpoint, was similar in the ...

Apixaban is being investigated within the EXPANSE Clinical Trials Program, which is projected to include nearly 60,000 patients worldwide across multiple indications and patient populations and ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

Update, March 1, 5 PM: Ramsay Baghadi of the RPM Report says that the Cardiorenal committee will take up the apixaban NDA on Mary 22 and the rivaroxaban supplemental NDA for the ACS indication on ...